<?xml version="1.0" encoding="utf-8"?> <rss version="2.0"> <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/"> <title>Lazar Partners</title> <link>https://www.globenewswire.com/rssfeed/organization/jmKgiuGqLE1iv9pe0MdYUQ==</link> <description>Contains the last 20 releases</description> <copyright>Copyright 2017, Lazar Partners</copyright> <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor> <lastBuildDate>Thu, 28 Sep 2017 12:30:00 GMT</lastBuildDate> <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/09/28/1157593/0/en/American-Heart-Association-s-New-Scientific-Statement-Deems-the-Corus-CAD-Test-Valid-and-Useful-for-Clinicians-Evaluating-Obstructive-CAD.html</guid> <link>https://www.globenewswire.com/news-release/2017/09/28/1157593/0/en/American-Heart-Association-s-New-Scientific-Statement-Deems-the-Corus-CAD-Test-Valid-and-Useful-for-Clinicians-Evaluating-Obstructive-CAD.html</link> <title>American Heart Association's New Scientific Statement Deems the Corus CAD Test Valid and Useful for Clinicians Evaluating Obstructive CAD </title> <description><![CDATA[<p><em><p>Scientific Statement Spotlights New Technologies in Expressed Genome Research That Further Precision Medicine in Cardiac Care</p></em></p><p>REDWOOD CITY, CA--(Marketwired - Sep 28, 2017) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today that in a Scientific Statement by the American Heart Association, the <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/" title="Corus® CAD">Corus® CAD</a> blood test was evaluated and "deemed to be valid and useful" in the workup of patients with suspected coronary artery disease (CAD).<sup>1</sup> CAD is one of the leading causes of death in the U.S. resulting in one in seven deaths.<sup>2</sup></p>]]></description> <pubDate>Thu, 28 Sep 2017 12:30 GMT</pubDate> <dc:identifier>1157593</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CardioDx</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/08/08/1157590/0/en/UPDATE-WATS3D-Shown-to-be-over-4X-More-Effective-in-Detecting-High-Grade-Dysplasia-and-Esophageal-Adenocarcinoma.html</guid> <link>https://www.globenewswire.com/news-release/2017/08/08/1157590/0/en/UPDATE-WATS3D-Shown-to-be-over-4X-More-Effective-in-Detecting-High-Grade-Dysplasia-and-Esophageal-Adenocarcinoma.html</link> <title>UPDATE - WATS3D Shown to be over 4X More Effective in Detecting High-Grade Dysplasia and Esophageal Adenocarcinoma </title> <description><![CDATA[<p><em><p>New results published in Gastrointestinal Endoscopy</p></em></p><p>SUFFERN, NY--(Marketwired - Aug 8, 2017) - CDx Diagnostics, developer of the WATS<sup>3D</sup> biopsy, or Wide Area Transepithelial Sampling with 3D Tissue Analysis for the detection and surveillance of Barrett's esophagus today announced the publication of new, pivotal, multicenter, crossover data in the latest issue of <em>Gastrointestinal Endoscopy</em>. The study found that WATS<sup>3D </sup>increased the detection of High-Grade Dysplasia and Esophageal Adenocarcinoma (HGD/EAC) by more than 400% compared to the standard Seattle protocol random forceps biopsy, even when those random biopsies are carefully performed in academic centers by some of the world's most experienced endoscopists. </p>]]></description> <pubDate>Tue, 08 Aug 2017 17:19 GMT</pubDate> <dc:identifier>1157590</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CDx Diagnostics</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="http://media.marketwire.com/attachments/201708/88609_Venn-Diagram.jpg"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2017/08/08/1157590/0/en/UPDATE-WATS3D-Shown-to-be-over-4X-More-Effective-in-Detecting-High-Grade-Dysplasia-and-Esophageal-Adenocarcinoma.html"> <img src="http://media.marketwire.com/attachments/201708/88609_Venn-Diagram.jpg" width="600" align="left" border="0" alt="Photo" title="Detection of HGD/EAC with WATS3D Compared with Seattle Protocol FB" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/08/08/1157585/0/en/WATS3D-Shown-to-be-over-4X-More-Effective-in-Detecting-High-Grade-Dysplasia-and-Esophageal-Adenocarcinoma.html</guid> <link>https://www.globenewswire.com/news-release/2017/08/08/1157585/0/en/WATS3D-Shown-to-be-over-4X-More-Effective-in-Detecting-High-Grade-Dysplasia-and-Esophageal-Adenocarcinoma.html</link> <title>WATS3D Shown to be over 4X More Effective in Detecting High-Grade Dysplasia and Esophageal Adenocarcinoma </title> <description><![CDATA[<p><em><p>New results published in Gastrointestinal Endoscopy</p></em></p><p>SUFFERN, NY--(Marketwired - Aug 8, 2017) - CDx Diagnostics, developer of the <a rel="nofollow" href="https://www.wats3d.com/" title="WATS3D">WATS3D</a> biopsy, or Wide Area Transepithelial Sampling with 3D Tissue Analysis for the detection and surveillance of Barrett's esophagus today announced the publication of new, pivotal, multicenter, crossover data in the latest issue of <em>Gastrointestinal Endoscopy</em>. The study found that WATS<sup>3D</sup> increased the detection of High-Grade Dysplasia and Esophageal Adenocarcinoma (HGD/EAC) by more than 400% compared to the standard Seattle protocol random forceps biopsy, even when those random biopsies are carefully performed in academic centers by some of the world's most experienced endoscopists. </p>]]></description> <pubDate>Tue, 08 Aug 2017 11:00 GMT</pubDate> <dc:identifier>1157585</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CDx Diagnostics</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="http://media.marketwire.com/attachments/201708/88609_Venn-Diagram.jpg"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2017/08/08/1157585/0/en/WATS3D-Shown-to-be-over-4X-More-Effective-in-Detecting-High-Grade-Dysplasia-and-Esophageal-Adenocarcinoma.html"> <img src="http://media.marketwire.com/attachments/201708/88609_Venn-Diagram.jpg" width="600" align="left" border="0" alt="Photo" title="Detection of HGD/EAC with WATS3D Compared with Seattle Protocol FB" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/07/05/1157581/0/en/VIVUS-Announces-Settlement-with-Actavis-on-Qsymia-R-Patent-Litigation.html</guid> <link>https://www.globenewswire.com/news-release/2017/07/05/1157581/0/en/VIVUS-Announces-Settlement-with-Actavis-on-Qsymia-R-Patent-Litigation.html</link> <title>VIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation </title> <description><![CDATA[<p>CAMPBELL, CA--(Marketwired - Jul 5, 2017) - VIVUS, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="VVUS">VVUS</ticker>) announced today that it has entered into a settlement agreement with Actavis Laboratories FL (Actavis) resolving patent litigation related to Qsymia® (phentermine and topiramate extended-release) capsules CIV. The litigation, which has been pending in the U.S. District Court for the District of New Jersey since 2014, resulted from the submission by Actavis of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market generic versions of Qsymia. The settlement agreement permits Actavis to begin selling a generic version of Qsymia on December 1, 2024, or earlier under certain circumstances. In the event of a launch earlier than December 1, 2024, VIVUS will receive a royalty on sales of the generic version of Qsymia. </p>]]></description> <pubDate>Wed, 05 Jul 2017 20:15 GMT</pubDate> <dc:identifier>1157581</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>VIVUS Inc.</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/04/12/1157577/0/en/New-Study-Published-in-The-American-Journal-of-Medicine-Expands-the-Clinical-Evidence-Underscoring-the-Value-of-the-Corus-R-CAD-Blood-Test-to-Help-Safely-Direct-Cardiovascular-Care.html</guid> <link>https://www.globenewswire.com/news-release/2017/04/12/1157577/0/en/New-Study-Published-in-The-American-Journal-of-Medicine-Expands-the-Clinical-Evidence-Underscoring-the-Value-of-the-Corus-R-CAD-Blood-Test-to-Help-Safely-Direct-Cardiovascular-Care.html</link> <title>New Study Published in The American Journal of Medicine Expands the Clinical Evidence Underscoring the Value of the Corus(R) CAD Blood Test to Help Safely Direct Cardiovascular Care </title> <description><![CDATA[<p><em><p>PRESET Registry Demonstrates the Corus CAD Blood Test Was Associated with Cardiac Referrals, and the Test Reduced Potentially Unnecessary Cardiac Workup of Patients</p></em></p><p>REDWOOD CITY, CA--(Marketwired - Apr 12, 2017) - <a rel="nofollow" href="http://www.cardiodx.com/" title="CardioDx, Inc.">CardioDx, Inc.</a>, a molecular diagnostics company specializing in <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/corus-cad-video" title="cardiovascular genomics">cardiovascular genomics</a>, announced today the publication of results from the multi-center, community-based PRESET Registry in the peer-reviewed journal, <em>The American Journal of Medicine.</em><sup>1</sup> The study results provided further confirmation of the clinical utility of the <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/product-overview" title="">Corus<sup>®</sup> CAD test</a> to help clinicians in real-world practice determine if their patients' symptoms are due to a blockage in the heart arteries, and if referral to cardiology or to advanced cardiac testing was necessary. Previously validated with a 96% negative predictive value and 89% sensitivity, the Corus CAD test is a precision medicine blood test that integrates age, sex, and gene expression levels into a single score indicating the current likelihood of a significant narrowing or blockage in the coronary arteries, also known as obstructive* coronary artery disease (CAD). </p>]]></description> <pubDate>Wed, 12 Apr 2017 12:00 GMT</pubDate> <dc:identifier>1157577</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CardioDx</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/06/1157574/0/en/PROMISE-Substudy-Results-Published-in-the-American-Heart-Journal-Provide-Independent-Validation-of-the-Clinical-Value-of-the-Corus-R-CAD-Blood-Test-to-Accurately-Identify-Patients-.html</guid> <link>https://www.globenewswire.com/news-release/2017/02/06/1157574/0/en/PROMISE-Substudy-Results-Published-in-the-American-Heart-Journal-Provide-Independent-Validation-of-the-Clinical-Value-of-the-Corus-R-CAD-Blood-Test-to-Accurately-Identify-Patients-.html</link> <title>PROMISE Substudy Results, Published in the American Heart Journal, Provide Independent Validation of the Clinical Value of the Corus(R) CAD Blood Test to Accurately Identify Patients with Obstructive CAD </title> <description><![CDATA[<p><em><p>Large NHLBI-Sponsored Substudy Corroborate Findings from Previous Validation Studies Demonstrating that Corus CAD Significantly Identifies Obstructive CAD and Predicts Future Clinical Events</p></em></p><p>REDWOOD CITY, CA--(Marketwired - Feb 6, 2017) - <a rel="nofollow" href="http://www.cardiodx.com/" title="CardioDx, Inc.">CardioDx, Inc.</a>, a molecular diagnostics company specializing in <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/corus-cad-video" title="cardiovascular genomics">cardiovascular genomics</a>, announced today the publication of a peer-reviewed substudy of the National Heart, Lung and Blood Institute (NHLBI)-funded PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial in the <em>American Heart Journal</em>, which assessed the Corus CAD test's ability to predict future clinical events.<sup>1</sup> Previously validated for the detection of obstructive* coronary artery disease (CAD) with a 96% negative predictive value and 89% sensitivity, Corus CAD is a simple blood test, incorporating age, sex, and gene expression measurements into a single score (1-40 scale) that indicates the current likelihood of obstructive CAD.<sup>2</sup></p>]]></description> <pubDate>Mon, 06 Feb 2017 13:00 GMT</pubDate> <dc:identifier>1157574</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CardioDx</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/11/14/1157569/0/en/CardioDx-Announces-Final-Endpoint-Results-from-the-PRESET-Registry-at-the-AHA-Scientific-Sessions-2016.html</guid> <link>https://www.globenewswire.com/news-release/2016/11/14/1157569/0/en/CardioDx-Announces-Final-Endpoint-Results-from-the-PRESET-Registry-at-the-AHA-Scientific-Sessions-2016.html</link> <title>CardioDx Announces Final Endpoint Results from the PRESET Registry at the AHA Scientific Sessions 2016 </title> <description><![CDATA[<p><em><p>Data Reinforce the Strong Evidence Base Supporting the Clinical Utility of the CorusĀ® CAD Blood Test in Real-World Practice</p></em></p><p>REDWOOD CITY, CA--(Marketwired - Nov 14, 2016) - CardioDx, Inc., a molecular diagnostics company specializing in <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/corus-cad-video" title="cardiovascular genomics">cardiovascular genomics</a>, announced results from the final endpoint analysis of the multi-center, community-based patient registry called the PRESET Registry (NCT01677156, A Registry to Evaluate Patterns of Care Associated with the Use of Corus CAD in Real World Clinical Care Settings). This analysis showed that the age, sex, and gene expression score (ASGES) derived from the <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/product-overview" title="Corus CAD blood test">Corus CAD blood test</a> has clinical utility in the evaluation of outpatients presenting with stable symptoms suggestive of obstructive* coronary artery disease (CAD). Clinicians referred 10% of patients with low <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/product-overview" title="Corus CAD test">Corus CAD test</a> scores (predefined as scores ≤ 15) versus 44% of patients with elevated scores (predefined as scores > 15) for further evaluation by cardiology or advanced cardiac testing (unadjusted Odds Ratio (OR) = 0.15, p < 0.0001; adjusted OR after accounting for clinical covariates = 0.18, p < 0.001.) Major adverse events and revascularization were noted in 3/252 (1.2%) patients with low Corus CAD scores and 14/314 (4.5%) patients with elevated Corus CAD scores (p < 0.03). The data was presented at the American Heart Association Scientific Sessions 2016, which took place on November 12-16 in New Orleans, La.</p>]]></description> <pubDate>Mon, 14 Nov 2016 13:30 GMT</pubDate> <dc:identifier>1157569</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CardioDx</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/07/13/1157566/0/en/Motif-Bio-Files-Registration-Statement-for-Proposed-U-S-Public-Offering-of-American-Depositary-Shares-and-Applies-for-NASDAQ-Listing.html</guid> <link>https://www.globenewswire.com/news-release/2016/07/13/1157566/0/en/Motif-Bio-Files-Registration-Statement-for-Proposed-U-S-Public-Offering-of-American-Depositary-Shares-and-Applies-for-NASDAQ-Listing.html</link> <title>Motif Bio Files Registration Statement for Proposed U.S. Public Offering of American Depositary Shares and Applies for NASDAQ Listing </title> <description><![CDATA[<p>LONDON, UNITED KINGDOM--(Marketwired - Jul 13, 2016) - Motif Bio plc (<exchange name="AIM">AIM</exchange>: <ticker name="MTFB">MTFB</ticker>), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed public offering of American Depositary Shares ("ADSs"). Motif Bio has also applied to have its ADSs listed on the NASDAQ Global Select Market under the ticker symbol "MTFB". Following completion of the offering of the ADSs, Motif Bio's ordinary shares will continue to trade on the AIM market of the London Stock Exchange. The number of ADSs to be offered and the price per ADS for the offering have not yet been determined. </p>]]></description> <pubDate>Wed, 13 Jul 2016 06:00 GMT</pubDate> <dc:identifier>1157566</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Motif Bio </dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/06/01/1157564/0/en/Khush-F-Mehta-Joins-CardioDx-as-Chief-Executive-Officer.html</guid> <link>https://www.globenewswire.com/news-release/2016/06/01/1157564/0/en/Khush-F-Mehta-Joins-CardioDx-as-Chief-Executive-Officer.html</link> <title>Khush F. Mehta Joins CardioDx as Chief Executive Officer </title> <description><![CDATA[<p><em><p>Seasoned Healthcare Executive Appointed to Lead Company Growth</p></em></p><p>REDWOOD CITY, CA--(Marketwired - Jun 1, 2016) - <a rel="nofollow" href="http://www.cardiodx.com/" title="CardioDx, Inc.">CardioDx, Inc.</a>, a molecular diagnostics company specializing in <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/corus-cad-video" title="cardiovascular genomics">cardiovascular genomics</a>, announced today the appointment of Khush Mehta as President, Chief Executive Officer, and a member of the Board of Directors of CardioDx. With a proven track record for commercial success and execution in the global healthcare industry, Mehta will help drive the organization to the next level of commercial growth, value creation for its stakeholders, and the expansion of the company's product portfolio through innovation and partnerships. He will focus on overseeing the day-to-day operations and accelerating profitable growth in the near and long-term. As CEO, Mehta succeeds David Levison, who has been named the Chief Strategy Officer of the company. </p>]]></description> <pubDate>Wed, 01 Jun 2016 12:30 GMT</pubDate> <dc:identifier>1157564</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CardioDx </dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/05/21/1157562/0/en/New-Data-Demonstrate-That-WATS3D-Is-4X-More-Effective-Than-the-Seattle-Random-Biopsy-Protocol-in-the-Detection-of-High-Grade-Dysplasia-and-Esophageal-Adenocarcinoma.html</guid> <link>https://www.globenewswire.com/news-release/2016/05/21/1157562/0/en/New-Data-Demonstrate-That-WATS3D-Is-4X-More-Effective-Than-the-Seattle-Random-Biopsy-Protocol-in-the-Detection-of-High-Grade-Dysplasia-and-Esophageal-Adenocarcinoma.html</link> <title>New Data Demonstrate That WATS3D Is 4X More Effective Than the Seattle Random Biopsy Protocol in the Detection of High-Grade Dysplasia and Esophageal Adenocarcinoma </title> <description><![CDATA[<p><em><p>Results From a Pivotal Prospective Randomized Crossover Study Conducted at 14 Major Academic Gastroenterology Centers to Be Presented at Digestive Disease Week</p></em></p><p>SUFFERN, NY--(Marketwired - May 21, 2016) - CDx Diagnostics today announced final data from a multicenter, prospective, randomized, crossover study demonstrating a fourfold increase in the detection of High-Grade Dysplasia and Esophageal Adenocarcinoma (HGD/EAC) using wide-area transepithelial sampling with three dimensional tissue analysis (WATS<sup>3D</sup>). In this study, WATS<sup>3D</sup> was compared with the Seattle random forceps biopsy protocol used for the endoscopic surveillance of patients with Barrett's esophagus. The study, "<em>Increased Detection of Barrett's Esophagus-Associated Neoplasia Using Wide Area Transepithelial Sampling in Conjunction with 4-Quadrant Forceps Biopsies: Final Results from a Multi-Center, Prospective, Randomized Trial</em>," is being presented during Digestive Disease Week (DDW) 2016, taking place from May 21-24, 2016 in San Diego, California.</p>]]></description> <pubDate>Sat, 21 May 2016 16:00 GMT</pubDate> <dc:identifier>1157562</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CDx Diagnostics</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="http://media.marketwire.com/attachments/201605/TN-96757_HGD-EAC.jpg"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2016/05/21/1157562/0/en/New-Data-Demonstrate-That-WATS3D-Is-4X-More-Effective-Than-the-Seattle-Random-Biopsy-Protocol-in-the-Detection-of-High-Grade-Dysplasia-and-Esophageal-Adenocarcinoma.html"> <img src="http://media.marketwire.com/attachments/201605/TN-96757_HGD-EAC.jpg" width="600" align="left" border="0" alt="Photo" title="TN-96757_HGD-EAC.jpg" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/05/18/1157560/0/en/Renew-Medical-Launches-New-Solution-to-Help-Prevent-Accidental-Bowel-Leakage.html</guid> <link>https://www.globenewswire.com/news-release/2016/05/18/1157560/0/en/Renew-Medical-Launches-New-Solution-to-Help-Prevent-Accidental-Bowel-Leakage.html</link> <title>Renew Medical Launches New Solution to Help Prevent Accidental Bowel Leakage </title> <description><![CDATA[<p><em><p>The Renew Insert Gives Patients the Confidence to Live an Active Life Without Worrying About Embarrassing Moments</p></em></p><p>FOSTER CITY, CA--(Marketwired - May 18, 2016) - Renew Medical Inc. (Renew) announced today the U.S. launch of the Renew Insert, an innovative silicone rectal insert device now available by prescription for patients with Accidental Bowel Leakage (ABL) in the United States. The Center for Disease Control estimates that ABL or fecal or bowel incontinence affects 17% of people 65 years of age or older.<sup>1</sup> A majority of ABL sufferers report a significant quality of life disruption, yet only a small number of those affected (approximately one in 10) have been clinically diagnosed.<sup>2</sup> </p>]]></description> <pubDate>Wed, 18 May 2016 13:00 GMT</pubDate> <dc:identifier>1157560</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Renew Medical </dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="http://media.marketwire.com/attachments/201605/TN-96654_RenewMedical.jpg"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2016/05/18/1157560/0/en/Renew-Medical-Launches-New-Solution-to-Help-Prevent-Accidental-Bowel-Leakage.html"> <img src="http://media.marketwire.com/attachments/201605/TN-96654_RenewMedical.jpg" width="600" align="left" border="0" alt="Photo" title="TN-96654_RenewMedical.jpg" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/05/17/1157558/0/en/CDx-Diagnostics-to-Unveil-New-Data-Demonstrating-a-Significant-Advance-in-the-Prevention-of-the-Most-Rapidly-Growing-Cancer-in-the-U-S.html</guid> <link>https://www.globenewswire.com/news-release/2016/05/17/1157558/0/en/CDx-Diagnostics-to-Unveil-New-Data-Demonstrating-a-Significant-Advance-in-the-Prevention-of-the-Most-Rapidly-Growing-Cancer-in-the-U-S.html</link> <title>CDx Diagnostics to Unveil New Data Demonstrating a Significant Advance in the Prevention of the Most Rapidly Growing Cancer in the U.S. </title> <description><![CDATA[<p><em><p>Final Results From a Multi-Center, Prospective, Randomized Clinical Trial to Be Presented at Digestive Disease Week 2016</p></em></p><p>SUFFERN, NY--(Marketwired - May 17, 2016) - <strong> </strong><a rel="nofollow" href="http://www.cdxdiagnostics.com/" title="CDx Diagnostics">CDx Diagnostics</a> today announced that results from a multi-center, prospective, randomized clinical trial demonstrating that WATS<sup>3D</sup> (Wide Area Transepithelial Sampling with 3D Tissue Analysis) sharply increases the detection of esophageal dysplasia (precancer), will be presented at Digestive Disease Week® 2016 (DDW), taking place from May 21-24 in San Diego, Calif.</p>]]></description> <pubDate>Tue, 17 May 2016 13:00 GMT</pubDate> <dc:identifier>1157558</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CDx Diagnostics</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/04/04/1157556/0/en/PROMISE-Trial-Substudy-Demonstrates-That-the-Corus-CAD-Blood-Test-Is-Associated-With-Clinical-Events-Among-Patients-Being-Evaluated-for-Suspected-Obstructive-Coronary-Artery-Diseas.html</guid> <link>https://www.globenewswire.com/news-release/2016/04/04/1157556/0/en/PROMISE-Trial-Substudy-Demonstrates-That-the-Corus-CAD-Blood-Test-Is-Associated-With-Clinical-Events-Among-Patients-Being-Evaluated-for-Suspected-Obstructive-Coronary-Artery-Diseas.html</link> <title>PROMISE Trial Substudy Demonstrates That the Corus CAD Blood Test Is Associated With Clinical Events Among Patients Being Evaluated for Suspected Obstructive Coronary Artery Disease </title> <description><![CDATA[<p><em><p>Data From Large NHLBI-Sponsored, Multi-Center Study Presented at the 65th American College of Cardiology Annual Scientific Meeting</p></em></p><p>REDWOOD CITY, CA--(Marketwired - Apr 4, 2016) - <a rel="nofollow" href="http://www.cardiodx.com/" title="CardioDx, Inc.">CardioDx, Inc.</a>, a molecular diagnostics company specializing in <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/corus-cad-video" title="cardiovascular genomics">cardiovascular genomics</a>, announced today results from a genomic substudy of the NHLBI-funded Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial in nondiabetic patients receiving the Corus CAD blood test. The test integrates age, sex and gene expression into a single score (1-40 scale) corresponding to the likelihood of obstructive coronary artery disease (CAD).* Findings from the substudy were presented at the 65<sup>th</sup> American College of Cardiology Annual Scientific Meeting, on April 3, 2016, in Chicago, IL. </p>]]></description> <pubDate>Mon, 04 Apr 2016 12:30 GMT</pubDate> <dc:identifier>1157556</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CardioDx</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/03/02/1157554/0/en/Commentary-in-The-American-Journal-of-Medicine-Reinforces-the-Value-of-the-Corus-CAD-Test-in-Evaluating-Symptomatic-Patients-With-Suspected-Obstructive-Coronary-Artery-Disease.html</guid> <link>https://www.globenewswire.com/news-release/2016/03/02/1157554/0/en/Commentary-in-The-American-Journal-of-Medicine-Reinforces-the-Value-of-the-Corus-CAD-Test-in-Evaluating-Symptomatic-Patients-With-Suspected-Obstructive-Coronary-Artery-Disease.html</link> <title>Commentary in The American Journal of Medicine Reinforces the Value of the Corus CAD Test in Evaluating Symptomatic Patients With Suspected Obstructive Coronary Artery Disease </title> <description><![CDATA[<p>REDWOOD CITY, CA--(Marketwired - Mar 2, 2016) - <a rel="nofollow" href="http://www.cardiodx.com/" title="CardioDx, Inc.">CardioDx, Inc.</a>, a molecular diagnostics company specializing in <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/corus-cad-video" title="cardiovascular genomics">cardiovascular genomics</a>, announced today that a Commentary entitled <em>A Novel Diagnostic Approach for Evaluating Suspected Coronary Artery Disease</em> (CAD) appears in the March online issue of <em>The American Journal of Medicine </em>(AJM). The commentary by William E. Boden, M.D., FACC, FAHA, of Chief of Medicine, Samuel S. Stratton VA Medical Center, and Professor of Medicine at Albany Medical College, Albany, NY, highlights the inefficiencies in the current diagnostic pathway for chest pain patients with suspected CAD and the need to shift physician decision-making for this common clinical disorder from routine cardiology specialty referral to the primary care physician and practicing internist. Boden highlights the important role of the Corus CAD blood test in helping clinicians more efficiently and effectively rule out obstructive CAD (particularly in low-risk patients) as compared with the more traditional diagnostic pathway that typically results in more expensive, procedurally-directed management that may also pose potential risks to patients. </p>]]></description> <pubDate>Wed, 02 Mar 2016 13:30 GMT</pubDate> <dc:identifier>1157554</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CardioDx</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/12/14/1157550/0/en/Timothy-Henn-Experienced-Genomics-Diagnostics-and-Life-Sciences-Executive-Joins-CardioDx-as-Chief-Financial-Officer.html</guid> <link>https://www.globenewswire.com/news-release/2015/12/14/1157550/0/en/Timothy-Henn-Experienced-Genomics-Diagnostics-and-Life-Sciences-Executive-Joins-CardioDx-as-Chief-Financial-Officer.html</link> <title>Timothy Henn, Experienced Genomics Diagnostics and Life Sciences Executive, Joins CardioDx as Chief Financial Officer </title> <description><![CDATA[<p>REDWOOD CITY, CA--(Marketwired - Dec 14, 2015) - <a rel="nofollow" href="http://www.cardiodx.com/" title="CardioDx, Inc.">CardioDx, Inc.</a>, a molecular diagnostics company specializing in <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/corus-cad-video" title="cardiovascular genomics">cardiovascular genomics</a>, announced today the appointment of Timothy Henn as Chief Financial Officer of the company. </p>]]></description> <pubDate>Mon, 14 Dec 2015 13:00 GMT</pubDate> <dc:identifier>1157550</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CardioDx</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/11/10/1157546/0/en/Multi-Center-Community-Based-Patient-Registry-Interim-Results-Presented-at-the-AHA-Scientific-Sessions-Support-the-Clinical-Utility-of-the-Corus-R-CAD-Test-in-the-Assessment-of-Obs.html</guid> <link>https://www.globenewswire.com/news-release/2015/11/10/1157546/0/en/Multi-Center-Community-Based-Patient-Registry-Interim-Results-Presented-at-the-AHA-Scientific-Sessions-Support-the-Clinical-Utility-of-the-Corus-R-CAD-Test-in-the-Assessment-of-Obs.html</link> <title>Multi-Center, Community-Based Patient Registry Interim Results Presented at the AHA Scientific Sessions Support the Clinical Utility of the Corus(R) CAD Test in the Assessment of Obstructive Coronary Artery Disease </title> <description><![CDATA[<p><em><p>Interim Results From the PRESET Registry Reinforce the Established Clinical Evidence Base Supporting the Adoption of the Corus CAD Test in the Primary Care Setting</p></em></p><p>REDWOOD CITY, CA--(Marketwired - Nov 10, 2015) -  CardioDx, Inc., a molecular diagnostics company specializing in <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/corus-cad-video" title="cardiovascular genomics">cardiovascular genomics</a>, announced today results from a multi-center, community-based patient registry called the PRESET Registry which found that patients with symptoms of obstructive coronary artery disease (CAD)* and who had low <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/product-overview" title="Corus® CAD test">Corus® CAD test</a> scores had an 82% decreased odds of referral for further cardiac evaluation versus patients with elevated Corus CAD test scores.<sup>1</sup> The Corus CAD test is a blood-based test that integrates age, sex, and gene expression levels into a single score indicating the current likelihood of a significant narrowing or blockage of the coronary arteries. The data was presented at American Heart Association Scientific Sessions 2015 in Orlando, Fl. on November 7-11, 2015.</p>]]></description> <pubDate>Tue, 10 Nov 2015 13:11 GMT</pubDate> <dc:identifier>1157546</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CardioDx</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/10/27/1157542/0/en/New-Data-Presented-at-UEG-Week-Shows-Use-of-WATS3D-Significantly-Increases-Detection-of-Esophageal-Pre-Cancer.html</guid> <link>https://www.globenewswire.com/news-release/2015/10/27/1157542/0/en/New-Data-Presented-at-UEG-Week-Shows-Use-of-WATS3D-Significantly-Increases-Detection-of-Esophageal-Pre-Cancer.html</link> <title>New Data Presented at UEG Week Shows Use of WATS3D Significantly Increases Detection of Esophageal Pre-Cancer </title> <description><![CDATA[<p><em><p>Compared to Standard Forceps Biopsy Alone, WATS3D Enhanced the Detection Rate of Barrett's Esophagus by 83.0% and Dysplasia by 88.5% in Multi-Center Community-Based Study</p></em></p><p>BARCELONA, SPAIN--(Marketwired - Oct 27, 2015) - <a rel="nofollow" href="http://www.wats3d.com/" title="CDx Diagnostics">CDx Diagnostics</a> today announced new data from a prospective multi-center community-based study demonstrating a significant increase in detection of esophageal pre-cancer and further validating the benefit of using the <a rel="nofollow" href="https://www.youtube.com/watch?v=L-nQn_KHhcE&feature=youtu.be" title="WATS3D">WATS3D</a> three-dimensional computer-assisted biopsy in community-based practices. The results were announced in an oral presentation today at United European Gastroenterology (UEG) Week 2015, taking place in Barcelona, Spain from October 24-28, 2015. </p>]]></description> <pubDate>Tue, 27 Oct 2015 13:30 GMT</pubDate> <dc:identifier>1157542</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CDx Diagnostics</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/10/21/1157538/0/en/Large-Multi-Center-Study-Demonstrates-Significant-Increase-in-Detection-of-Esophageal-Pre-Cancer-With-Use-of-WATS3D-Biopsy.html</guid> <link>https://www.globenewswire.com/news-release/2015/10/21/1157538/0/en/Large-Multi-Center-Study-Demonstrates-Significant-Increase-in-Detection-of-Esophageal-Pre-Cancer-With-Use-of-WATS3D-Biopsy.html</link> <title>Large Multi-Center Study Demonstrates Significant Increase in Detection of Esophageal Pre-Cancer With Use of WATS3D Biopsy </title> <description><![CDATA[<p><em><p>Adding WATS3D Improved the Detection of Barrett's Esophagus by 153% and Dysplasia by 242% in Community-Based Settings</p></em></p><p>HONOLULU, HI--(Marketwired - Oct 21, 2015) - <strong> </strong><a rel="nofollow" href="http://www.wats3d.com/" title="CDx Diagnostics">CDx Diagnostics</a> announced today new data from a prospective multi-center study of more than 12,800 patients demonstrating a significant increase in detection of esophageal pre-cancer, including Barrett's esophagus and dysplasia, with the use of <a rel="nofollow" href="https://youtu.be/L-nQn_KHhcE" title="WATS3D biopsy">WATS3D biopsy</a>, a three dimensional computer-assisted biopsy system, in community-based settings. The results were announced during a podium presentation today at the American Gastroenterology (ACG) 2015 Annual Scientific Meeting, taking place in Honolulu, Hawaii, from October 16 - 21, 2015.</p>]]></description> <pubDate>Wed, 21 Oct 2015 20:30 GMT</pubDate> <dc:identifier>1157538</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CDx Diagnostics</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/10/14/1157534/0/en/CDx-Diagnostics-to-Present-New-Data-Demonstrating-Increased-Detection-of-Esophageal-Pre-Cancer-Using-WATS3D.html</guid> <link>https://www.globenewswire.com/news-release/2015/10/14/1157534/0/en/CDx-Diagnostics-to-Present-New-Data-Demonstrating-Increased-Detection-of-Esophageal-Pre-Cancer-Using-WATS3D.html</link> <title>CDx Diagnostics to Present New Data Demonstrating Increased Detection of Esophageal Pre-Cancer Using WATS3D </title> <description><![CDATA[<p><em><p>Results From Large Prospective Multi-Center Community-Based Study of More Than 12,000 Patients to Be Presented at the ACG 2015 Annual Scientific Meeting</p></em></p><p>SUFFERN, NY--(Marketwired - Oct 14, 2015) -  <a rel="nofollow" href="http://www.cdxdiagnostics.com/" title="CDx Diagnostics">CDx Diagnostics</a> today announced the presentation of results from a prospective multi-center study demonstrating that the WATS<sup>3D</sup> three dimensional computer-assisted biopsy system markedly increased the detection of esophageal pre-cancer in a community-based setting. Including more than 12,000 patients, the results from this large study will be unveiled during a podium presentation at the American College of Gastroenterology (ACG) 2015 Annual Scientific Meeting, taking place in Honolulu, Hawaii, from October 16 -21, 2015. </p>]]></description> <pubDate>Wed, 14 Oct 2015 14:03 GMT</pubDate> <dc:identifier>1157534</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CDx Diagnostics</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/09/30/1157530/0/en/CardioDx-Announces-Positive-Data-From-a-Large-Primary-Care-Registry-on-the-Impact-of-the-Corus-CAD-Test-in-the-Assessment-of-Obstructive-Coronary-Artery-Disease-in-Women.html</guid> <link>https://www.globenewswire.com/news-release/2015/09/30/1157530/0/en/CardioDx-Announces-Positive-Data-From-a-Large-Primary-Care-Registry-on-the-Impact-of-the-Corus-CAD-Test-in-the-Assessment-of-Obstructive-Coronary-Artery-Disease-in-Women.html</link> <title>CardioDx Announces Positive Data From a Large Primary Care Registry on the Impact of the Corus CAD Test in the Assessment of Obstructive Coronary Artery Disease in Women </title> <description><![CDATA[<p><em><p>Subgroup Analysis From the PRESET Registry Presented at The North American Menopause Society 2015 Annual Meeting</p></em></p><p>REDWOOD CITY, CA--(Marketwired - Sep 30, 2015) - CardioDx, Inc., a molecular diagnostics company specializing in <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/corus-cad-video" title="cardiovascular genomics">cardiovascular genomics</a>, announced today results from a subgroup analysis of the primary efficacy endpoint of the community-based patient registry, the PRESET Registry.<sup>1</sup> This analysis evaluated how the <a rel="nofollow" href="http://www.cardiodx.com/corus-cad/product-overview" title="Corus® CAD test">Corus® CAD test</a>, a blood-based test that integrates age, sex, and gene expression levels into a single score indicating the likelihood of obstructive CAD, impacted clinicians' diagnostic strategy for cardiac evaluation of women. Data from the subgroup analysis will be presented at The North American Menopause Society (NAMS) Annual Meeting on October 1, 2015 in Las Vegas, Nevada. </p>]]></description> <pubDate>Wed, 30 Sep 2015 12:00 GMT</pubDate> <dc:identifier>1157530</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CardioDx</dc:contributor> <dc:modified>Fri, 27 Oct 2017 06:58 GMT</dc:modified> </item> </channel> </rss>